Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Holly Lee

Showing results (21-30 of 50) with videos related to

Pageof 5
Sort By:
Nature Reviews. Clinical Oncology|July 3, 2024
Just scratching the surface: novel treatment approaches for multiple myeloma targeting cell membrane proteinsPaola Neri, Noémie Leblay, Holly Lee, et al.
Amyloid : the International Journal of Experimental and Clinical Investigation : the Official Journal of the International Society of Amyloidosis|June 7, 2021
Treatment response measurements and survival outcomes in a cohort of newly diagnosed AL amyloidosisVictor H Jimenez-Zepeda, Holly Lee, Sylvia McCulloch, et al.
Annals of Hematology|July 21, 2021
N-Terminal pro-brain natriuretic peptide (NTproBNP) in patients with symptomatic multiple myeloma: report from a single institutionVictor H Jimenez-Zepeda, Holly Lee, Jason Tay, et al.
European Journal of Haematology|November 16, 2020
The impact of COVID-19 in the management of AL amyloidosis and Immunoglobulin Deposition Disease: A single-center experienceHolly Lee, Jason Tay, Peter Duggan, et al.
Amyloid : the International Journal of Experimental and Clinical Investigation : the Official Journal of the International Society of Amyloidosis|March 28, 2022
Suboptimal response for AL amyloidosis: is it time for early switch? Experience from a single amyloid programRobert Puckrin, Holly Lee, Jason Tay, et al.
Indian Journal of Hematology & Blood Transfusion : an Official Journal of Indian Society of Hematology and Blood Transfusion|November 8, 2021
Cyclophosphamide, Bortezomib and Methylprednisolone (CyBorMe) for the Treatment of AL Amyloidosis: Initial Experience From a Single CenterVictor H Jimenez-Zepeda, Holly Lee, Nowell Fine, et al.
Clinical Lymphoma, Myeloma & Leukemia|November 17, 2022
Real-world Outcomes With Cumulative Bortezomib Dose and Efficacy in the Treatment of Transplant-ineligible Multiple Myeloma With Cyclophosphamide, Bortezomib, and DexamethasoneChunpeng Nie, Holly Lee, Jason Tay, et al.
Leukemia & Lymphoma|December 6, 2023
Daratumumab for the treatment of relapsed/refractory AL amyloidosis: experience from the amyloidosis Program of Calgary (APC)Daniel Levin, Ellen Lewis, Sylvia McCulloch, et al.
Clinical Lymphoma, Myeloma & Leukemia|January 9, 2023
Monoclonal Gammopathy of Undetermined Significance in Patients With Transthyretin Amyloidosis (ATTR): Analysis Using the iStopMM CriteriaEllen Lewis, Holly Lee, Nowell Fine, et al.
Clinical Lymphoma, Myeloma & Leukemia|November 22, 2017
Early Relapse for Multiple Myeloma Patients Undergoing Single Autologous Stem Cell Therapy: A Single-center ExperienceHolly Lee, Peter Duggan, Ahsan Chaudhry, et al.
Pageof 5

Showing results (21-30 of 50) with videos related to

Sort By:
Pageof 5
Nature Reviews. Clinical Oncology|July 3, 2024
Just scratching the surface: novel treatment approaches for multiple myeloma targeting cell membrane proteinsPaola Neri, Noémie Leblay, Holly Lee, et al.
Amyloid : the International Journal of Experimental and Clinical Investigation : the Official Journal of the International Society of Amyloidosis|June 7, 2021
Treatment response measurements and survival outcomes in a cohort of newly diagnosed AL amyloidosisVictor H Jimenez-Zepeda, Holly Lee, Sylvia McCulloch, et al.
Annals of Hematology|July 21, 2021
N-Terminal pro-brain natriuretic peptide (NTproBNP) in patients with symptomatic multiple myeloma: report from a single institutionVictor H Jimenez-Zepeda, Holly Lee, Jason Tay, et al.
European Journal of Haematology|November 16, 2020
The impact of COVID-19 in the management of AL amyloidosis and Immunoglobulin Deposition Disease: A single-center experienceHolly Lee, Jason Tay, Peter Duggan, et al.
Amyloid : the International Journal of Experimental and Clinical Investigation : the Official Journal of the International Society of Amyloidosis|March 28, 2022
Suboptimal response for AL amyloidosis: is it time for early switch? Experience from a single amyloid programRobert Puckrin, Holly Lee, Jason Tay, et al.
Indian Journal of Hematology & Blood Transfusion : an Official Journal of Indian Society of Hematology and Blood Transfusion|November 8, 2021
Cyclophosphamide, Bortezomib and Methylprednisolone (CyBorMe) for the Treatment of AL Amyloidosis: Initial Experience From a Single CenterVictor H Jimenez-Zepeda, Holly Lee, Nowell Fine, et al.
Clinical Lymphoma, Myeloma & Leukemia|November 17, 2022
Real-world Outcomes With Cumulative Bortezomib Dose and Efficacy in the Treatment of Transplant-ineligible Multiple Myeloma With Cyclophosphamide, Bortezomib, and DexamethasoneChunpeng Nie, Holly Lee, Jason Tay, et al.
Leukemia & Lymphoma|December 6, 2023
Daratumumab for the treatment of relapsed/refractory AL amyloidosis: experience from the amyloidosis Program of Calgary (APC)Daniel Levin, Ellen Lewis, Sylvia McCulloch, et al.
Clinical Lymphoma, Myeloma & Leukemia|January 9, 2023
Monoclonal Gammopathy of Undetermined Significance in Patients With Transthyretin Amyloidosis (ATTR): Analysis Using the iStopMM CriteriaEllen Lewis, Holly Lee, Nowell Fine, et al.
Clinical Lymphoma, Myeloma & Leukemia|November 22, 2017
Early Relapse for Multiple Myeloma Patients Undergoing Single Autologous Stem Cell Therapy: A Single-center ExperienceHolly Lee, Peter Duggan, Ahsan Chaudhry, et al.
Pageof 5